EyePoint Pharmaceuticals Files 8-K on Financials
Ticker: EYPT · Form: 8-K · Filed: May 8, 2024 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | May 8, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, corporate-actions
Related Tickers: EYPT
TL;DR
EYPT filed an 8-K on May 8th detailing financials and operations.
AI Summary
EyePoint Pharmaceuticals, Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as pSivida Corp. and pSivida LTD.
Why It Matters
This 8-K filing provides crucial updates on EyePoint Pharmaceuticals' financial performance and operational status, which is essential for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Registrant
- pSivida Corp. (company) — Former company name
- pSivida LTD (company) — Former company name
- May 08, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on EyePoint Pharmaceuticals, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on May 8, 2024.
What were EyePoint Pharmaceuticals' previous names?
EyePoint Pharmaceuticals, Inc. was formerly known as pSivida Corp. and pSivida LTD.
In which state was EyePoint Pharmaceuticals incorporated?
EyePoint Pharmaceuticals, Inc. was incorporated in Delaware.
What is the principal executive office address for EyePoint Pharmaceuticals?
The principal executive office address for EyePoint Pharmaceuticals is 480 Pleasant Street, Watertown, Massachusetts 02472.
Filing Stats: 428 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-05-08 07:05:11
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind
Filing Documents
- eypt-20240508.htm (8-K) — 37KB
- eypt-ex99_1.htm (EX-99.1) — 36KB
- img96707757_0.jpg (GRAPHIC) — 5KB
- img96707757_1.jpg (GRAPHIC) — 68KB
- img96707757_2.jpg (GRAPHIC) — 48KB
- 0000950170-24-055055.txt ( ) — 357KB
- eypt-20240508.xsd (EX-101.SCH) — 23KB
- eypt-20240508_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On May 8, 2024, EyePoint Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2024 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of EyePoint Pharmaceuticals, Inc., dated May 8, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: May 8, 2024 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer